Summary slide.png (118.29 kB)

Long-Term Assessment of Lurasidone in Schizophrenia: Post Hoc Analysis of a 12-Month, Double Blind, Active-Controlled Trial and 6-Month Open-Label Extension Study

figure

posted on 2020-10-22, 12:31 authored by Preeya J. Patel, Christian Weidenfeller, Andrew P. Jones, Jens Nilsson, Jay Hsu

Article full text

The above summary slide represents the opinions of the authors. For a full list of declarations, including funding and author disclosure statements, please see the full text online (see “read the peer-reviewed publication” opposite).

History

References

https://link.springer.com/article/10.1007/s40120-020-00221-4

Usage metrics

Read the peer-reviewed publication

Long-Term Assessment of Lurasidone in Schizophrenia: Post Hoc Analysis of a 12-Month, Double Blind, Active-Controlled Trial and 6-Month Open-Label Extension Study

Neurology and Therapy

Keywords

Atypical antipsychotic Cardiometabolic Lurasidone Metabolic syndrome Prolactin Risperidone Schizophrenia Switch

Licence

CC BY-NC 4.0

Long-Term Assessment of Lurasidone in Schizophrenia: Post Hoc Analysis of a 12-Month, Double Blind, Active-Controlled Trial and 6-Month Open-Label Extension Study

History

References

Usage metrics

Read the peer-reviewed publication

Categories

Keywords

Licence

Exports